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Bacterial biofilms play an important role in urinary tract infections (UTIs), being responsible for persistence infections causing
relapses and acute prostatitis. Bacterial forming biofilm are difficult to eradicate due to the antimicrobial resistant phenotype
that this structure confers being combined therapy recommended for the treatment of biofilm-associated infections. However,
the presence of persistent cells showing reduced metabolism that leads to higher levels of antimicrobial resistance makes the search
for new therapeutic tools necessary. Here, a review of these new therapeutic approaches is provided including catheters coated with
hydrogels or antibiotics, nanoparticles, iontophoresis, biofilm enzyme inhibitors, liposomes, bacterial interference, bacteriophages,
quorum sensing inhibitors, low-energy surface acoustic waves, and antiadhesion agents. In conclusion, new antimicrobial drugs
that inhibit bacterial virulence and biofilm formation are needed.
1. Urinary Tract Infections
Urinary tract infections (UTIs) are one of themost important
causes of morbidity and health care spending affecting
persons of all ages, including youngwomen, children, and the
elderly. It is estimated that approximately 40% of women have
had a UTI at some time in their lives [1].
These infections are traditionally classified based on clin-
ical symptoms, laboratory data, andmicrobiological findings.
UTIs are categorized as cystitis (infection of the lower urinary
tract or bladder), pyelonephritis (infection affecting the
upper urinary tract or the kidneys), and prostatitis (prostate
inflammation) [2]. More recently, however, UTIs have been
clinically classified into groups based on clinical factors and
their impact onmorbidity and treatment [3].These categories
are acute uncomplicated cystitis in young women, recurrent
cystitis in youngwomen, acute uncomplicated pyelonephritis
in youngwomen, complicatedUTI, UTI related to indwelling
catheters, UTI in men, and asymptomatic bacteriuria [3].
Sexually active young women are at greater risk of
presenting UTIs (especially uncomplicated cystitis) due to
their anatomy (short urethra) and certain behavioural factors.
Uncomplicated cystitis is limited to a few pathogens, being
the most frequent Escherichia coli, causing approximately
80% of cystitis [3].
Recurrent UTIs appear in more than 20% of young
women with acute cystitis and are divided into relapse (if all
the infections are caused by the same microorganism) and
reinfection (if the episodes are caused by different microor-
ganisms). Relapses are categorized as complicated UTIs and
require longer courses of antibiotics. Relapses in women have
been related to the capacity of the microorganisms to form
biofilm [4]. The clinical spectrum of complicated UTIs may
range from cystitis to urosepsis with septic shock.
Acute pyelonephritis is a potentially organ- and/or life-
threatening infection that often leads to renal scarring. Acute
pyelonephritis results from bacterial invasion of the renal
parenchyma. Bacteria usually reach the kidney by ascending
from the lower urinary tract but may also reach the kidney
via the bloodstream. The time of diagnosis and management
of this UTI are very important for the impact on patient
outcomes.
Acute bacteria prostatitis is a common but important
genitourinary infection in men and is presented as a febrile
UTI [5]. Acute bacteria prostatitis is most commonly caused
by an ascendant UTI, with E. coli [6], Proteus mirabilis,
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Pseudomonas aeruginosa, Klebsiella, Enterococcus spp., and
Serratia spp. being the microorganisms most frequently
involved [5]. Acute bacterial prostatitis can be caused by a
sexually transmitted disease (gonorrhoea), although it is also
very common in patients with benign prostatic hyperplasia
following a UTI. The incidence of this infection is approxi-
mately 1-2 cases per 10,000 males.
Another important type of UTI is the asymptomatic
bacteriuria which is defined as the presence of more than
100,000CFU per mL of voided urine in subjects with no
symptoms of UTI and can originate in the bladder or the
kidneys [7]. Pregnant and elderly women have the highest
rates of incidence of asymptomatic bacteriuria. Treatment is
not recommended in the routine practice for asymptomatic
bacteriuria, except in pregnant women and individuals
undergoing invasive procedures [8]. The microorganisms
most frequently found as a cause of asymptomatic bacteriuria
are E. coli, P. aeruginosa, and Gram-positive bacteria such as
Enterococcus and S. aureus [9].
Urinary catheters are a route of entry for bacteria.
Between 10 and 20% of hospitalized patients are catheterized.
Catheter-associated UTIs account for 40% of all nosocomial
infections and are the most common source of Gram-
negative bacteremia in hospitalized patients [10]. The role
of biofilm forming pathogens in catheter-associated UTIs
is explained in the present review. The pathogens most
frequently found in this type of UTI are E. coli, Proteus,
Enterococcus, Pseudomonas, Enterobacter, Serratia, and Can-
dida spp. [11], being normally acquired exogenously via
manipulation of the catheter and drainage device.
2. Bacterial Biofilms
Biofilms are currently estimated to be responsible for over
65% of nosocomial infections and 80% of all microbial
infections [12].
Biofilm is defined as a microbiologically derived ses-
sile community characterized by cells that are irreversibly
attached to a substratum or interface or each other and
embedded in a matrix of extracellular polymeric substances
(EPS) that they have produced. This matrix accounts for
about 90% biomass [13], exhibiting an altered phenotype
with respect to growth rate and gene transcription [14, 15].
Environmental changes are responsible for the transition
from planktonic growth to biofilm [16] and cause changes
in the expression of surface molecules, virulence factors, and
metabolic status, allowing the bacteria to acquire properties
that enable their survival in unfavourable conditions [17, 18].
Biofilms are ubiquitous and can be found in awide variety
of sites or niches. They can be formed by one or multiple
bacterial species forming complex structures.
Biofilm formation is carried out in five steps which are
represented in Figure 1 [19].
(i) Reversible attachment of planktonic bacteria to sur-
faces.Thefirst attachment of the bacteria is influenced
by attractive or repelling forces that vary depending
on nutrient levels, pH, and the temperature of the





Figure 1: Biofilm formation steps. (i) Reversible attachment of
planktonic bacteria to surfaces. (ii) Irreversible attachment to
surfaces. (iii) Formation of the external matrix. (iv) Biofilms acquire
a three-dimensional structure. (v) Biofilm detachment.
chemotaxis play an important role avoiding the action
of the hydrodynamic and repulsive forces as well as
selecting the surface [22], respectively.
(ii) Irreversible attachment to surfaces. In the case of E.
coli, it is mediated by type 1 pili, curli fibres, and
antigen 43 that also favours the interbacterial inter-
actions [23–26]. In the case of P. aeruginosa as well as
other Pseudomonas species, transition from reversible
to irreversible attachment has been well studied. It
has been observed that P. fluorescens requires an ATP-
binding cassette (ABC) encoded by the lap genes for
carrying out this process [27]. On the other hand, P.
aeruginosa requires the SadB protein and the two-
component regulatory systems BfiSR for irreversible
attachment [28, 29].
(iii) Formation of a complex layer of biomolecules [30]
and EPS secretion that constitute the external matrix.
Production of polysaccharides in biofilm forming
strains facilitates aggregation, adherence, and surface
tolerance, allowing better surface colonization [31].
The E. coli matrix is composed of cellulose [32],
polyglucosamine, and colonic acid [33]. The P. aerug-
inosamatrix is composed of two types of polysaccha-
rides: the capsular and aggregative polysaccharides.
Alginate is the main and most studied capsular
polysaccharide produced by P. aeruginosa [34] and
maintains the characteristics of protective dynamic
polymers that present one or more cells. On the other
hand, aggregative polysaccharides confer structural
integrity to the biofilm [35]. Nucleic acids, such as
DNA, proteins, surfactants, lipids, glycolipids, mem-
brane vesicles, and ions such as calcium can also be
found forming part of the matrix composition and
may play an important role in the characteristics that
biofilm structure confers to the cells.
(iv) Biofilms acquire a three-dimensional structure when
they reach maturity. These three-dimensional struc-
tures with macrocolony morphology depend on
self-produced extracellular matrix components. EPS,
adhesins, amyloid-forming proteins, and exopolysac-
charides (all included in biofilm matrix) are required
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to generate these structures in which gradients of
nutrients, water, signaling compounds or waste prod-
ucts are present along the different areas of biofilm
[36], conditioning the metabolism of the cells.
(v) When biofilms are fully mature, detachment may
occur. Detachment allows cells to again take on a
planktonic state and can thereby form biofilm in
other settings. It has been proposed that bacteria
detachment could be caused by active mechanisms
initiated by the bacteria themselves such as enzymatic
degradation of the biofilm matrix and quorum sens-
ing in response to environmental changes related to
nutrition levels and oxygen depletion [37] and by
passive mechanisms mediated by external forces and
erosion [38–41]. Biofilm dispersal is an important
step in a high number of bacterial species, allowing
their transmission from environment to human host,
between hosts, and even within a single host spread-
ing the infection [39]. The role of c-di-GMP levels in
the biofilm dispersion has recently been determined,
being a secondmessenger used in signal transduction
in a high number of bacteria species [42]. Thus, it has
been proposed that high levels of c-di-GMP increase
the sessile behaviour of the bacteria, while low levels
increase the motility of the bacteria [43]. c-di-GMP
affects EPS production, biofilm formation, cell length,
and swimmingmotility in E. coli [44]. Nowadays, this
second messenger is the subject of further research
(for further review see [45, 46]).
Biofilms can also be found inside the host cells form-
ing intracellular structures. The first report of intracellular
bacterial communities (IBC) with biofilm-like properties was
described in uropathogenic E. coli (UPEC) [24, 46]. It has
been observed that a high number of IBC are associated with
the development of chronic cystitis [47, 48]. The presence
of IBC has also been described in children with recurrent
urinary infections by light and confocal laser scanning
microscopy. These structures have been associated with an
E. coli strain presenting type 1, P, and S/F1C fimbriae and K1
capsule genes [49], indicating the important role of adhesion
structures in biofilm formation.
3. Biofilms and Urinary Tract Infections
As previously commented, bacterial biofilms play an impor-
tant role in medicine. According to the NIH, biofilm forming
bacteria involved up to 80%of all infections [19], with urology
being one of the main fields in which biofilm can become
a serious problem. Biofilm can be found in the urothelium,
prostate stones, and implanted foreign bodies [50].
Bacteria adhered to the uroepithelium and forming
biofilm can invade the renal tissue causing pyelonephritis [51]
and even be responsible for chronic bacterial prostatitis. In
the latter case, an additional problem is the difficulties to
diagnosis this prostatitis because the colonized bacteria may
not be present in the prosthetic secretion or the urine samples
[52].
Biofilms can not only develop into urethral stents but
they can also form on catheters causing their blockage.
Thus, catheter-associated UTI (CAUTI) is one of the most
common care-associated infections around the world [53].
Several reports have associated CAUTI with more than
40% of health-care-associated infections in the United States
[53]. Commensal perineal flora is involved in most CAUTI
cases. More than 90% of these infections are monomicrobial
with E. coli, Pseudomonas aeruginosa, enterococci, Candida,
Klebsiella, or Enterobacter spp. being the most frequently iso-
lated pathogens [54]. The environmental conditions created
on the catheter surface make it an ideal site for bacterial
attachment and formation of biofilm structures [55]. In this
type of medical device, microorganisms producing urease,
an enzyme that hydrolyzes urea to ammonium ions, can
cause encrustation, formation of infected bladder calculi,
and urinary obstruction. The formation of ammonium ions
increases the pH of the urine, finally causing the precipitation
of magnesium and calcium phosphate crystals [56, 57]. The
pH value at which precipitation occurs is called nucleation
pH [58].These crystals can form a layer that protects bacteria
from the antimicrobial effects of compounds used for coating
or impregnating the catheters [59]. Proteus mirabilis is the
main source of this problem in urinary infections [60]
and presents several virulence factors that allow it to form
biofilm such as mannose-resistant fimbriae, capsules, and
urease [61]. Other microorganisms such as Proteus vulgaris
and Providencia rettgeri also have the capacity to produce
crystalline biofilms [56].
In addition, biofilm formation may even result in the
increased ability of strains causing acute prostatitis to persist
in the prostatic secretory system and lead to the recurrent
UTIs characteristic of chronic bacterial prostatitis [62]. In
fact, it has been shown that after an episode of acute prostatitis
cultures of expressed prostatic secretions are still positive 3
months after the end of a 6-week therapeutic regimen in one-
third of men [63]. It has been reported that 63% of E. coli
strains collected from patients with prostatitis were “in vitro”
biofilm producers in contrast to 40% of E. coli strains causing
cystitis and pyelonephritis [62]. Biofilm formation may be
the reason why bacterial prostatitis is so difficult to eradicate
using conventional treatments.
4. Biofilms and Persistent Infections
Acute UTI caused by bacteria can lead to recurrent infection,
which is defined as a “reinfection” when it involves a strain
other than that causing the original infection, or it is defined
as a “relapse” when it is caused by the same strain as that
involved in the original UTI. Recurrent UTIs are common
among young, healthy women, despite their urinary tracts
generally being anatomically and physiologically normal
[64]. Approximately 25% of women with an episode of
acute cystitis later develop recurrent UTI, which represents
a substantial burden to the healthcare system. Consequently,
the number of studies to elucidate the factors predisposing
recurrent UTI in order to develop effective methods of
prevention and therapy is encouraged to be increased [65].
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Several studies observed that most of isolates collected from
patients with relapse infections were biofilm producers “in
vitro” [66]. Relapse by uropathogenic E. coli (UPEC) has
been related to the ability of pathogenic strains to form
biofilm. In these cases, biofilm production may be the key
determinant for the persistence of UPEC in the vaginal
reservoir, the bladder epithelial cells, or both.Thus, in a study
carried out in theHospital Clinic of Barcelona, 43 ambulatory
female patients ≥ 18 years of age were included following
an index episode of cystitis or pyelonephritis, and they were
clinically followed for at least 6 months, collecting urine
cultures every month. Eighty E. coli strains were collected, 27
causing relapses and 53 causing reinfections. Among them,
74% and 42% were “in vitro” biofilm producers, respectively,
demonstrating a relationship between persistence, relapse,
and biofilm formation [4].
5. Biofilms and Antimicrobial Resistance
One of the most important advantages of biofilm status is the
antimicrobial resistance shown by these structures. Biofilm
can be up to 1000-fold more resistant to antibiotics than
planktonic cells due to several mechanisms [67–71].
(i) Limitation of antibiotic diffusion through the matrix.
Some antimicrobial agents are unable to diffuse
through the matrix or sometimes the time required
for the antibiotic to penetrate into biofilm is longer
than the duration of treatment or the antibiotic life-
time. Thus, for example, aminoglycosides penetrate
more slowly through the matrix than 𝛽-lactams.
(ii) Transmission of resistance genes within the com-
munity can occur. Thus, plasmids, transposons, and
other mobile genetic elements can be transmitted
between cells forming biofilm by their close relation-
ship, spreading resistance markers.
(iii) Expression of efflux pumps is also considered a
mechanism for antimicrobial resistance not only in
planktonic cells but also in biofilms structures [72,
73].
(iv) Inactivation of the antibiotic by changes in metal ion
concentrations and pH values. Antibiotics able to
diffuse can be inactivated by the pH inside biofilm.
This change in the pH could antagonise the activity of
the antibiotic.
(v) The presence of metabolically inactive cells denomi-
nated persister cells. Persisters are dormant variants
of regular cells, not mutants, which may form small
colony variants that are high tolerant to extracellu-
lar stresses. They are highly tolerant to antibiotics
forming a reservoir of surviving cells [74] able to
rebuild the biofilm population [74–76]. The tol-
erance to antibiotics could be explained by their
reduced metabolism and their ability to switch off
the antibiotic targets, such as protein synthesis or
DNA replication. The acquisition of this persister
status is mediated by toxin-antitoxin modules [77].
Taking into account that several antimicrobial agents,
such as penicillin, only kill actively growing bacteria,
persister cells are a problem for biofilm eradica-
tion. Proteins required for maintaining persisters
may represent excellent targets for the discovery of
compounds capable of effectively treating chronic
infections and biofilm-related infections.
The level of resistance depends on biofilm stage. Thus, in
the reversible attachment step, antibiotics and antibiofilm are
the most effective, because the bacteria have not connected
themselves in the matrix and are vulnerable to the action of
antibiotics and host immune system [19].
Once the bacteria begin to secrete EPS and the attachment
becomes irreversible, biofilm is more resistant to antibiotics
and host immune responses [78]. The matrix protects the
cells within it from exposure to innate immune defences
and antimicrobial treatments [79, 80] and facilitates com-
munication among them through biochemical signals. Some
biofilms have been found to contain water channels that
help to distribute nutrients and signalling molecules [81].
Other studies suggest that resistance of bacteria in biofilm
to a high number of antibiotics can be due to the density
and physiological state of the culture rather than their
residence within biofilm [82]. In addition, the spread of
resistance markers and virulence factors can be promoted
through their structure [83]. It has been demonstrated that
the mode of growth of biofilm increases the ability of S.
aureus to disseminate plasmid-borne antibiotic resistance
determinants by both conjugation and mobilization of these
mobile genetic elements [84]. This phenomenon could be
facilitated by the close cell-to-cell contact inside biofilms and
also by the stabilization of these contacts that may be favored
by the biofilm matrix.
6. Antimicrobial Treatment of Biofilms
Treatment of biofilm-associated infections is a field that
requires further study, in part due to the high levels of
antibiotic resistance exhibited by biofilm structures conferred
in part by the exopolysaccharide matrix. Several studies
recommend combination therapy as the treatment of choice
in biofilm-associated infections, withmacrolides being one of
the first antibiotics chosen [85]. Macrolides (erythromycin,
clarithromycin, and azithromycin) present high “in vitro”
and “in vivo” antibiofilm activity against biofilm-associated
infections caused by Gram-negative bacteria inhibiting the
production of a key component of the matrix, alginate [85].
Macrolides have been shown to be effective against P. aerug-
inosa, another Gram-negative bacteria, and more recently
against Staphylococcus spp. biofilms [86]. This antibiofilm
activity was first described “in vitro” exposing P. aerugi-
nosa sessile cells to clarithromycin and erythromycin [86].
The antibiotic combination, clarithromycin plus vancomycin,
demonstrated the ability to eradicate both biofilm and plank-
tonic cells [87] as well as to eradicate biofilm on the titanium
washers used in animal experiments [88]. Roxithromycin
plus imipenem favour a higher penetration of neutrophils
into biofilm structure destabilizing the biofilm [89]. Con-
versely, macrolides have been shown to enhance biofilm
Advances in Biology 5
formation in Gram-positive bacteria due to an increase in
the expression of biofilm-related genes such as icaA, atlE,
fruA, pyrR, sarA, and sigB [90]. This fact has an important
clinical implication because the macrolide levels needed for
enhancing biofilm formation could be found in clinical niches
or settings.
Another approach using antimicrobials consists in coat-
ing and impregnating the catheters with these antimicrobial
agents. The aim of this procedure is to avoid bacterial attach-
ment to the catheter surface and the posterior development of
biofilm [91]. In this sense, the silver has also been used to coat
catheters because it has bactericidal actions. Silver has broad-
spectrum antimicrobial activity. The antimicrobial action of
silver compounds is proportional to the bioactive silver ion
released and its availability to interact with bacterial or fungal
cell membranes. It has been observed that silver alloy coating
prevents adherence and the growth of biofilm-embedded
bacteria by 50% [92, 93]. Synthetic cationic peptide variants
derived from natural peptides have been used as strategy to
target biofilm [94].
More recently, some substances showing antibacterial
properties, such as gendine (gentian violet plus chlorhex-
idine), nitrous oxide, and nitrofurazone (nitrofuran), have
been used to modify the surface of urinary catheters. How-
ever, the risk of using antibiotics to treat the catheter surface
may lead to the development of antimicrobial resistancewhen
the drug levels become subinhibitory [60].
7. New Trends in Antibiofilm Treatments
Biofilms eradication is difficult due to the high level of antimi-
crobial resistance showed by these structures. In spite of the
previously commented approaches, new therapeutic options
are being studied as an alternative to treatments with existing
antibiotics in order to avoid not only biofilm formation
but also the emergence of resistant bacterial populations in
underlying tissues. Here a review of these new approaches is
provided.
7.1. Catheters Coated withHydrogels or Antibiotics. Hydrogels
are cross-linked, insoluble, hydrophilic polymers that trap
water. This characteristic provides the catheter with an
increase in surface lubrication which consequently decreases
the bacterial adhesion to this surface and demonstrates a role
in the reduction of encrustation of catheters. However, the
ability of these hydrogels to prevent CAUT remains unclear
[95]. Kazmierska et al. [96] observed that a hydrogel layer
increased the aggregation of planktonic cells, causing an
increase in nucleated crystals, provoking more rapid catheter
blockage in comparison with the uncoated silicone. However,
this negative effect was suppressed when active agents were
added to the hydrogel.
In this sense, a high number of antimicrobial agents and
other chemical compounds have been used to coat catheters.
Silver alloy has been used in hydrogel-coated urinary catheter
observing a decrease of up to 45% of CAUTI [97, 98].
Minocycline-rifampicin-coated catheters have been shown to
inhibit the biofilm formation of Gram-positive and Gram-
negative pathogens, except P. aeruginosa and Candida spp.
[99]. However, one problem with this may be the possible
development of resistant phenotypes among the bacteria
[100]. However, no silver-resistant mutants were collected in
the aforementioned studies.
7.2. Nanoparticles. A nanoparticle is a microscopic particle
with a dimension of less than 100 nm. Nanoparticle research
is currently an area of intense scientific interest due to a
wide variety of potential applications in biomedical, optical,
and electronic fields. These particles have the capacity to
attach and penetrate into bacterial cells, disrupt the bacterial
membrane, and interact with chromosomal DNA [101].
Nanoparticles of MgF have been used for coating glass
surfaces observing an inhibition of biofilm formation by
both, E. coli and S. aureus [101]. Catheters have also been
coated with these nanoparticles and a significant reduction of
bacterial colonizationwas observed over a period of 1 week in
comparison with the catheter uncoated catheter control.This
group also demonstrated the antibacterial and antibiofilm
activity of yttriumfluoride (YF
3
) nanoparticleswhich showed
low solubility and provided extended protection. In addition,
another advantage of these nanoparticles was their low
cytotoxicity [102].
Microwave irradiated CaO nanoparticles (CaO-NPs)
have also shown the potential to inhibit biofilm formation
against Gram-negative and Gram-positive bacteria [103].
Silver nanoparticles have also been used for impregnating
medical devices due to the silver antimicrobial properties
previously commented in this review [104]. These nanopar-
ticles have been used in medical and pharmaceutical nano-
engineering applied to the delivery of therapeutic agents,
diagnostic approaches, and as part of biosensors [104].
Several studies have demonstrated the “in vivo” and “in vitro”
inhibition of biofilm formation by numerous bacterial species
and using determined nanoparticle concentrations. However,
the mechanism of action of silver nanoparticles remains
unknown [105].
Another aspect related to silver nanoparticles is the
toxicity to eukaryotic cells which remains uncharacterized.
7.3. Iontophoresis. Iontophoresis is a physical process in
which ions flow diffusively in a medium driven by an applied
electric field.Thismethod enhances the efficacy of antibiofilm
agents “in vitro” [106]. Thus, it has been observed that low
electrical currents enhance the activity of tobramycin and
biocides againstP. aeruginosa biofilm.However, this effect has
only been observed among those antibiotics that are effective
against planktonic cells [107]. Iontophoresis has also been
studied to prevent biofilm formation and encrustation by
P. mirabilis showing that the application of electric current
to these catheters fitted with silver electrodes significantly
decreased their encrustation [108]. Nevertheless, “in vivo”
studies have yet to be performed in this respect.
7.4. Enzyme Inhibitors. Urease, the enzyme that allows P.
mirabilis to hydrolyze urea to ammonium ions, has been
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an important target in the study of new antibiofilm com-
pounds. In this sense, fluorofamide has been a candidate
molecule because it is able to prevent the increase in pH by
Proteus mirabilis “in vitro”, thereby inhibiting the formation
of urea crystal and the subsequent encrustation and catheter
obstruction [109, 110]. Other natural compounds, such as
vanillic acid [111], natural plum juice [112], and germa-𝛾-
lactones [113], among others, presented the ability to strongly
inhibit bacterial growth as well as the formation of crystals in
catheters by the inhibition of the urease enzyme.
In one study Lu and Collins [114] generated a bacterio-
phage which expressed a biofilm-degrading enzyme during
infection.The enzyme associated with the bacteriophage was
DspB and it is produced by one species of Actinobacillus.
DspB hydrolyses a crucial adhesion needed for biofilm for-
mation and integrity in both E. coli and Staphylococcus [115]
and attacks the bacterial cells in the biofilm and the biofilm
matrix simultaneously. The percentage of eradication using
this bacteriophage-enzyme combination was about 99.9%
[114].
In recent years, the second messenger, c-di-GMP, has
been studied in depth because it is highly conserved among
bacterial species, being an important candidate for studies on
biofilm inhibition. c-di-GMP is synthetized via diguanylate
cyclases (DGC). Inhibition of DGC activity leads to a reduc-
tion in biofilm formation by a decrease in the intracellular
levels of c-di-GMP [116]. Several molecules have been shown
to inhibit biofilm formation on urinary catheters by P.
aeruginosa via an inhibition on the DGC WspR enzyme
and they have the ability to disperse formed biofilm of P.
aeruginosa and A. baumannii. These small molecules are
denominated LP 3134, LP 3145, LP 4010, and LP 1062 [117].
7.5. Liposomes. The use of liposomes could be one method
for improving the effectiveness of antibiotics [118]. They act
as carriers of drug molecules, increasing their length of life
[119] and reducing toxicity in the host [120, 121]. Liposome-
encapsulated antimicrobial agents have been successfully
tested in humans and in animal models, being directed
to eradicate protozoa, fungal, and bacterial infections [122,
123]. Liposomes can be applied in the eradication of formed
biofilm because when the antibiotic is encapsulated in a
liposome carrier it does not interact with the EPS, improving
its antibiofilm effect, and it is protected from degradation
by antibiotic-inactivating enzymes (such as 𝛽-lactamases)
which can appear in the biofilmmatrix [124].Thus, liposomal
containing tobramycin and bismuth reportedly penetrated
and killed bacteria in the core of the P. aeruginosa biofilms,
in contrast to both free compounds that only killed and
detached bacteria from the biofilm surface [125]. Liposomes
containing clarithromycin have been tested against biofilm-
forming P. aeruginosa, observing a significant reduction in
biofilm production as well as in bacterial twitching, swarm-
ing, and swimming motility. In addition, clarithromycin-
entrapped liposomes showed less cytotoxicity than the free
drug [126]. In spite of the excellent results obtained, more
studies are needed in CAUTI and other biofilm-related
infections.
7.6. Bacterial Interference. This method is related to the
antagonism between different bacteria species during the
colonization of surfaces and biofilm formation. Briefly, the
colonization of a surface by nonpathogenic bacteria could
prevent the adherence of pathogenic bacteria thereby avoid-
ing infection [60]. Several avirulent strains ofE. colihave been
used as a method to reduce urinary catheter colonization
by a wide variety of pathogens [127, 128]. Thus, the E.
coli HU2117 strain, derived from E. coli 83972, that causes
persistent colonization without symptomatic infection [129–
131], has been used for coating urinary catheters, observing
a reduction of biofilm formation by other pathogens [128].
This strain presented a deletion of the papG gene resulting
in a lack of P-fimbriae. The E. coli 83972 strain has also
been used for coating urinary catheters, demonstrating a
reduction in the development of UTIs in persons undergoing
an intermittent catheterization programme [132]. A study
performed among catheterized patients with spinal cord
injury who were inoculated with a nonpathogenic E. coli
strain in the bladder showed that these patients had less
probability of developing an episode of UTI during the one-
year follow-up period [133].
7.7. Bacteriophages. Bacteriophages are the natural predators
of bacteria. They are viruses that specifically infect bacteria.
Among them, lytic phages are able to disrupt the nor-
mal bacterial metabolism, favouring viral replication [134].
Phages have been used for treating some infectious diseases
in humans mainly related to S. aureus [135] due to their
bactericidal activity. The phage charcteristics that allow them
to control biofilm are the capacity to replicate at the site of
infection, the production of enzymes (depolymerases) that
degrade the EPS of the biofilm matrix [136–139], and their
capacity to propagate through the biofilm [140].These phages
have been incorporated into hydrogel-coating catheters, and
a reduction has been observed in biofilm formation by
Staphylococcus epidermidis and P. aeruginosa [141, 142]. In
addition, the use of lytic bacteriophages against established
biofilm of P.mirabilis and E. coli caused a reduction of three to
four log cycles [134].These lytic phages also prevented biofilm
formation on catheters coated with hydrogel containing
bacteriophages. The reduction of formation observed was
about 90% [134].
7.8. Quorum Sensing Inhibitors. Quorum sensing (QS) is
a cell-density-dependent chemical signalling system that
allows individual cells to release small signal molecules to the
surroundings to make their presence known [143]. The small
signal molecules are known as autoinducers and coordinate
cell-density-dependent gene expression [144]. QS is used to
coordinate gene expression and regulate numerous processes
that are involved in virulence such as motility and biofilm
formation [145] being necessary for planktonic bacteria to
adopt the biofilm phenotype.
An efficient quorum sensing inhibitor (QSI) should have
the following characteristics [146]:
(1) have a low molecular mass able to inhibit the expres-
sion of genes related to QS,
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(2) be highly specific for the QS-regulators,
(3) not show toxicity to the eukaryotic hosts,
(4) not interfere with the basal metabolic processes of
bacteria in order to avoid the development of resis-
tances,
(5) be chemically stable, resistant to host metabolism,
and able to reside in the host for a sufficient long time.
Several QSI have been identified to date, many hav-
ing been isolated from nature [147–151]. For example, the
pyrimidinone compound inhibits biofilm formation and
disrupts and removes the biofilm deposited. HSL analogues
are compounds analogous to the QS signal and compete with
the native signals for binding to the receptor, blocking QS,
and inhibiting biofilm formation in S. aureus [152]. Garlic
extract was found to enhance the susceptibility to tobramycin
by altering the architecture of the bacterial biofilms [150].
Peptides also show QSI activity. Thus, the RNAIII inhibiting
peptide was able to inhibit agr-mediated biofilm formation in
drug resistant S. epidermidis [153, 154].
7.9. Low-Energy Surface Acoustic Waves. It has been demon-
strated that surface acoustic waves (SAW) interfere with
adhesion of planktonic microorganisms to cellular surfaces
[155]. SAW reduces biofilm bioburden on catheter segments
in suspensions with several Gram-negative [156] and Gram-
positive bacteria as well as fungi indicating its efficacy against
a broad spectrum of microorganisms. Power intensities of 0.1
and 0.2mW/cm2, generating vibration frequencies of 95 KHz
and 220 kHz with acoustic pressure amplitudes of 0.1 and
0.22 kPa, respectively, were the conditions used in the “in
vitro” experiments on avoiding adhesion [157].
The efficacy of this approach was studied in a rabbit
model, and it was observed that catheter-associated vibrating
activators were found to maintain urine sterile for 7 days,
whereas control catheters (without vibrations) resulted in
bacteriuria within 1.5 days [157]. This effect was observed
against E. coli, Enterococcus faecalis, Candida albicans, and P.
mirabilis.
7.10. Antiadhesion Agents. The prophylaxis of UTIs using
antiadhesive compounds/molecules is currently an impor-
tant objective in clinical research [158].
The main characteristic of an antiadhesive compound
is that it should specifically interact with the adhesins of
the pathogen, inhibiting the union between pathogen and
eukaryotic cell [159, 160]. These antiadhesive compounds
cause a decrease in invasion or infection of host epithelial
cells, also avoiding recurrence. One of the compounds most
frequently studied is cranberry extract [161]. The antiadher-
ence effect of cranberry against uropathogenic E. coli (UPEC)
is due to the presence of A-type proanthocyanidin trimers in
the cranberry extract [162, 163] that acts as an antiadhesion
agent. Other antiadhesion agents are those denominated
mannosides, curlicides, and pilicides.These agents inhibit the
biogenesis of adhesins required for biofilm formation and
adhesion to epithelial cells. The most studied agents are the
mannosides that inhibit FimH attachment to host receptors.
FimH is the tip of the type 1 fimbriae of E. coli that mediates
the first step in biofilm formation. Mannosides seem to have
a good prophylactic role in UTIs caused by E. coli since
they not only interfered with adherence but also enhance
the effect of the antimicrobial agent cotrimoxazol [164]. In
this sense, nanodiamond particles, covently modified with
mannose moieties, are able to efficiently inhibit E. coli type
1 fimbriae-mediated adhesion to eukaryotic cells [165].
Salicylate is amember of a large group of pharmaceuticals
referred to as nonsteroidal anti-inflammatories and it is the
active component of the analgesic aspirin. Salicylate has
shown to decrease biofilm formation of UPEC inhibiting
type 1 fimbriae expression. In addition, the effect of salicylate
in biofilm reduction could be intensified by the decrease of
OmpA expression that causes a decrease in the extracellular
matrix [166].
In addition, bacterial biofilms seem to be reservoir for
molecules that act as antagonists of bacterial adhesion. An
example is a polysaccharide produce by E. coli that excludes
S. aureus from mixed E. coli and S. aureus biofilms [167].
In conclusion, the possible patient outcomes related
to biofilm-related infections make the in-depth search for
compounds with antibiofilm properties necessary in order
to prevent the formation of and/or disrupt the development
of biofilm. The ideal situation is a compound or a group
of compounds that present not only antibiofilm activity but
also the capacity to eradicate multidrug-resistant bacteria.
It is also important to study the antibiofilm activity of new
combinations of therapeutic strategies including new ones
and old antibiotics. Virulence factors should be considered
important targets for developing antivirulence compounds
that may be applied in the prevention and treatment of
infectious diseases.
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[12] U. Römling and C. Balsalobre, “Biofilm infections, their
resilience to therapy and innovative treatment strategies,” Jour-
nal of Internal Medicine, vol. 272, no. 6, pp. 541–561, 2012.
[13] H.-C. Flemming and J.Wingender, “The biofilmmatrix,”Nature
Reviews Microbiology, vol. 8, no. 9, pp. 623–633, 2010.
[14] R. M. Donlan, “Biofilms: microbial life on surfaces,” Emerging
Infectious Diseases, vol. 8, no. 9, pp. 881–890, 2002.
[15] R. M. Donlan and J. W. Costerton, “Biofilms: survival mecha-
nisms of clinically relevant microorganisms,” Clinical Microbi-
ology Reviews, vol. 15, no. 2, pp. 167–193, 2002.
[16] A. P. Lenz, K. S. Williamson, B. Pitts, P. S. Stewart, and
M. J. Franklin, “Localized gene expression in Pseudomonas
aeruginosa biofilms,” Applied and Environmental Microbiology,
vol. 74, no. 14, pp. 4463–4471, 2008.
[17] L. Zhang and T. Mah, “Involvement of a novel efflux system in
biofilm-specific resistance to antibiotics,” Journal of Bacteriol-
ogy, vol. 190, no. 13, pp. 4447–4452, 2008.
[18] J. Klebensberger, A. Birkenmaier, R. Geffers, S. Kjelleberg,
and B. Philipp, “SiaA and SiaD are essential for inducing
autoaggregation as a specific response to detergent stress in
Pseudomonas aeruginosa,” Environmental Microbiology, vol. 11,
no. 12, pp. 3073–3086, 2009.
[19] S. D. Stowe, J. J. Richards, A. T. Tucker, R. Thompson, C.
Melander, and J. Cavanagh, “Anti-biofilm compounds derived
from marine sponges,” Marine Drugs, vol. 9, no. 10, pp. 2010–
2035, 2011.
[20] K. P. Lemon, D. E. Higgins, and R. Kolter, “Flagellar motility is
critical for Listeriamonocytogenes biofilm formation,” Journal of
Bacteriology, vol. 189, no. 12, pp. 4418–4424, 2007.
[21] C. M. Toutain, N. C. Caizza, M. E. Zegans, and G. A. O’Toole,
“Roles for flagellar stators in biofilm formation by Pseudomonas
aeruginosa,” Research in Microbiology, vol. 158, no. 5, pp. 471–
477, 2007.
[22] T. Schmidt and A. Kirschning, “Total synthesis of carolacton,
a highly potent biofilm inhibitor,” Angewandte Chemie, vol. 51,
no. 4, pp. 1063–1066, 2012.
[23] P. N. Danese, L. A. Pratt, and R. Kolter, “Exopolysaccharide
production is required for development of Escherichia coli K-
12 biofilm architecture,” Journal of Bacteriology, vol. 182, no. 12,
pp. 3593–3596, 2000.
[24] G. G. Anderson, J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser,
and S. J. Hultgren, “Intracellular bacterial biofilm-like pods in
urinary tract infections,” Science, vol. 301, no. 5629, pp. 105–107,
2003.
[25] C. Beloin, A. Roux, and J. M. Ghigo, “Escherichia coli biofilms,”
Current Topics in Microbiology and Immunology, vol. 322, pp.
249–289, 2008.
[26] L. Cegelski, J. S. Pinkner, N. D. Hammer et al., “Small-molecule
inhibitors target Escherichia coli amyloid biogenesis and biofilm
formation,” Nature Chemical Biology, vol. 5, no. 12, pp. 913–919,
2009.
[27] S. M. Hinsa, M. Espinosa-Urgel, J. L. Ramos, and G. A. O’Toole,
“Transition from reversible to irreversible attachment dur-
ing biofilm formation by Pseudomonas fluorescens WCS365
requires an ABC transporter and a large secreted protein,”
Molecular Microbiology, vol. 49, no. 4, pp. 905–918, 2003.
[28] N. C. Caiazza and G. A. O’Toole, “SadB is required for the
transition from reversible to irreversible attachment during
biofilm formation by Pseudomonas aeruginosa PA14,” Journal
of Bacteriology, vol. 186, no. 14, pp. 4476–4485, 2004.
[29] O. E. Petrova and K. Sauer, “The novel two-component regula-
tory system BfiSR regulates biofilm development by controlling
the small RNA rsmZ throughCafA,” Journal of Bacteriology, vol.
192, no. 20, pp. 5275–5288, 2010.
[30] H. M. Lappin-Scott and C. Bass, “Biofilm formation: attach-
ment, growth, and detachment of microbes from surfaces,”
American Journal of Infection Control, vol. 29, no. 4, pp. 250–
251, 2001.
[31] H. Laue, A. Schenk, H. Li et al., “Contribution of alginate
and levan production to biofilm formation by Pseudomonas
syringae,”Microbiology, vol. 152, no. 10, pp. 2909–2918, 2006.
[32] X. Zogaj, W. Bokranz, M. Nimtz, and U. Römling, “Production
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